Medifast Reports $17.5 Million Third Quarter Loss
The company expects full-year revenue to reach up to $300 million after a challenging third quarter.
Updated on Oct. 26, 2026 in Economic Indicators
Live Poll
Do you trust the long-term outlook for traditional weight-loss companies?
Medifast reported a $17.5 million net loss for the third quarter of 2026 as revenue reached $72 million. This financial result highlights the current performance of the weight-loss company for households monitoring corporate earnings.
Why it matters
The company's performance reflects its ongoing financial trajectory as it navigates a period of net losses. Investors and observers of the weight-loss sector may watch these earnings reports to assess the company's ability to reach its full-year projections.
Medifast reported a $17.5 million net loss for the third quarter, which includes a loss per share of $1.57. While the company reported $72 million in revenue, it projects full-year revenue between $280 million and $300 million.
The players
Medifast
A Baltimore-based company that provides weight-loss programs and products.
The details
The reported loss reflects the company's financial standing for the three-month period ending in September 2026. Adjusted results show a loss of 19 cents per share for the quarter. Moving forward, Medifast has issued projections for the remainder of the year, anticipating fourth-quarter revenue to fall between $55 million and $75 million.
Timeline
Medifast reported its $17.5 million loss for Q3 2026.
The current fiscal quarter ends in December 2026.
Money Landscape
This earnings report positions Medifast within its broader fiscal cycle for the 2026 calendar year. The current performance is being measured against the company's updated revenue and loss projections for the full year.
Households tracking the company's financial stability should note the projected full-year loss of 70 cents to 45 cents per share. Individuals with questions regarding the impact of these corporate results on their own financial planning should consult a qualified financial professional.
The takeaway
Medifast is moving through a period of net losses while providing guidance for the final months of the year. Readers may want to monitor the company's stated revenue targets for the fourth quarter as an indicator of its financial progress.
What happens next
The company expects to conclude its current fiscal quarter in December 2026.
Further reading
For more insight into how company performance impacts market trends, visit Economic Indicators.
Live Poll
Do you trust the long-term outlook for traditional weight-loss companies?
